<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862366</url>
  </required_header>
  <id_info>
    <org_study_id>RC-P0004</org_study_id>
    <nct_id>NCT02862366</nct_id>
  </id_info>
  <brief_title>Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-</brief_title>
  <acronym>MICROP-SMP</acronym>
  <official_title>Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of Chronic Philadelphia Negative Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with myeloproliferative neoplasms Philadelphia chromosome negative (MPNsPh1-) such&#xD;
      as Essential thrombocytosis (ET), Polycythemia vera (PV) and Primary Myelofibrosis (PMF) have&#xD;
      a higher risk of arterial or deep-vein thrombosis. This is responsible for a significant&#xD;
      increase in mortality (up to 31% of increase in thrombosis risk in ET). Cellular inflation&#xD;
      and blood hyperviscosity, resulting from these diseases, fail to account for these&#xD;
      thromboses, as more than 50% of thrombotic complications happen under adapted antineoplastic&#xD;
      drug treatment.&#xD;
&#xD;
      These last years, cellular microparticles (MPs) have been shown to play a major role in&#xD;
      thrombogenesis. MPs are generated by apoptosis or the activation of malignant cells,&#xD;
      platelets, endothelial cells or monocytes. They are fragments of plasma membrane, smaller&#xD;
      than 1 µm, rich in phosphatidylserine, which can express the tissue factor and serve as&#xD;
      support for the coagulation factors. Increase in the plasma concentration of procoagulant&#xD;
      platelet microparticles has been demonstrated in other thrombotic diseases (acute coronary&#xD;
      syndrome, disseminated intravascular coagulation DIC, etc.). The working hypothesis is that&#xD;
      platelet microparticles are involved in the hypercoagulability of MPNs patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 25, 2016</completion_date>
  <primary_completion_date type="Actual">January 25, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the average number of microparticles detected by flow cytometry in all subgroup</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">128</enrollment>
  <condition>Myeloproliferative Neoplasm</condition>
  <arm_group>
    <arm_group_label>Primary Myelofibrosis (PMF)</arm_group_label>
    <description>Blood sampling during routine visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Essential thrombocytosis (ET)</arm_group_label>
    <description>Blood sampling during routine visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polycythemia vera (PV)</arm_group_label>
    <description>Blood sampling during routine visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Blood sampling every 6 month following the routine calendar of visit</description>
    <arm_group_label>Essential thrombocytosis (ET)</arm_group_label>
    <arm_group_label>Polycythemia vera (PV)</arm_group_label>
    <arm_group_label>Primary Myelofibrosis (PMF)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ET, PV or PMF. Healthy volunteers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for MNPs patients:&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  Establish MNPs Phi- diagnosis (ET, PV, MFP)&#xD;
&#xD;
          -  Consent to participate&#xD;
&#xD;
        Inclusion Criteria for healthy volunteers:&#xD;
&#xD;
          -  Healthy volunteers matched in age, sex with the MNPs patients, with a normal complete&#xD;
             blood and platelet count&#xD;
&#xD;
          -  No personal thromboembolic history&#xD;
&#xD;
          -  No known thromboembolic risk factor : thrombophilia, cancers, and other disease&#xD;
             associated with a thrombotic risk (Atrial fibrillation, etc.)&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Non smoker&#xD;
&#xD;
          -  For women, no hormonal contraceptives&#xD;
&#xD;
        Exclusion Criteria for MNPs patients:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patient unable to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnès Charpentier, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>GHICL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EFS</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHICL</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myeloproliferative neoplasms</keyword>
  <keyword>Circulating Procoagulants Microparticles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombophilia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

